Publications by authors named "Dimitrios Zisopoulos"

Claim this Profile
E
Effect of secukinumab on bone formation markers in patients with active ankylosing spondylitis.
Grigorios T Sakellariou, Maria Konsta, Ioanna Katsigianni, Dimitrios Deligeorgakis, Dimitrios Zisopoulos

Int J Rheum Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-IL5 Monoclonal Antibodies Reduce Asthma Exacerbations and Corticosteroids Dose in Three Eosinophilic Granulomatosis with Polyangiitis Case Reports.
Elpida Skouvaklidou, Maria Kipourou, Dimitrios Zisopoulos, Periklis Vounotrypidis, Konstantinos Katsoulis

Mediterr J Rheumatol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular acrosyndromes in young adult population. Definition of clinical symptoms and connections to joint hypermobility.
Periklis Vounotrypidis, Athina Pyrpasopoulou, Grigorios T Sakellariou, Dimitrios Zisopoulos, Nikoleta Kefala

Clin Rheumatol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Irini D Flouri, Theodora E Markatseli, Kyriaki A Boki, Ioannis Papadopoulos, Fotini N Skopouli, Dimitrios Zisopoulos

J Rheumatol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.
Nadia Boubouchairopoulou, Irini Flouri, Alexandros A Drosos, Kyriaki Boki, Loukas Settas, Dimitrios Zisopoulos

Clin Exp Rheumatol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
Irini Flouri, Theodora E Markatseli, Paraskevi V Voulgari, Kyriaki A Boki, Ioannis Papadopoulos, Dimitrios Zisopoulos

Semin Arthritis Rheum· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis